Imipenem and Cilastatin Sodium · Infectious Disease Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while cilastatin prevents imipenem degradation by inhibiting renal dehydropeptidase I.
Remimazolam Tosilate for Injection · Anesthesia/Sedation Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing sedation and anxiolysis.
Phase 3 pipeline
Avastin®, paclitaxel, carboplatin · Oncology This combination uses bevacizumab to inhibit tumor angiogenesis while paclitaxel and carboplatin work as chemotherapy agents to kill cancer cells.
BP102, paclitaxel, carboplatin · Oncology BP102 is a nanoparticle albumin-bound paclitaxel combined with carboplatin chemotherapy that disrupts microtubule dynamics and induces DNA crosslinking to kill cancer cells.
camrelizumab； famitinib malate · Oncology Camrelizumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction to enhance T-cell mediated anti-tumor immune response.
Camrelizumab Plus Chemotherapy · Oncology Camrelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses.
Carboplatin for Injection · Oncology Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing apoptosis.
Drug: Pegylated rhG-CSF: 100µg/kg · Oncology; Hematology Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.
Enzalutamide Soft Capsules · Oncology Enzalutamide is an androgen receptor inhibitor that blocks the binding and nuclear translocation of androgens, preventing androgen-driven gene transcription in prostate cancer cells.
Fluconazole capsule · Infectious Disease Fluconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.
Fluzoparib; Apatinib · Oncology Fluzoparib is a PARP inhibitor that blocks DNA repair, while apatinib is a tyrosine kinase inhibitor targeting VEGFR2, together enhancing anti-tumor effects through synthetic lethality and anti-angiogenesis.
Fuzuloparib , Abiraterone acetate and Prednisone · Oncology This combination uses fuzuloparib (a PARP inhibitor) to block DNA repair, combined with abiraterone acetate and prednisone to suppress androgen production and signaling in castration-resistant prostate cancer.
Herombopag tablets · Hematology Herombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on megakaryocyte progenitor cells.
Hetrombopag Olamine+Standard Therapy · Hematology Hetrombopag olamine is a thrombopoietin receptor agonist that stimulates platelet production to increase platelet counts.
HR17031 injection · Oncology HR17031 is an anti-angiogenic agent that inhibits vascular endothelial growth factor (VEGF) signaling to suppress tumor blood vessel formation.
HRS-4357 injection · Oncology HRS-4357 is an anti-angiogenic agent that inhibits vascular endothelial growth factor (VEGF) signaling to suppress tumor blood vessel formation.
HRS-4642 + AG · Oncology HRS-4642 is an anti-angiogenic tyrosine kinase inhibitor that blocks multiple receptor tyrosine kinases involved in tumor vascularization and growth.
HRS-8427 · Oncology HRS-8427 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells.
HRS-9231 · Oncology HRS-9231 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and angiogenesis.
INS068 injection · Oncology INS068 is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses.
Insulin Degludec Injection · Diabetes Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.
Irinotecan liposome、5-Fluorouracil、Leucovorin · Oncology This combination regimen uses liposomal irinotecan (a topoisomerase I inhibitor) plus 5-fluorouracil and leucovorin to inhibit DNA replication and repair in cancer cells.
Letrozole or Anastrozole Tablets · Oncology Letrozole and Anastrozole are aromatase inhibitors that block the conversion of androgens to estrogen, reducing estrogen levels in postmenopausal women with hormone receptor-positive breast cancer.
long-acting Octreotide. · Oncology; Endocrinology Long-acting octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors.
nab-paclitaxel; gemcitabine · Oncology nab-paclitaxel and gemcitabine work together as a chemotherapy combination to disrupt microtubule dynamics and inhibit DNA synthesis, respectively, to kill rapidly dividing cancer cells.
Noiiglutide Injection · Diabetes Noiiglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve blood glucose control.
Palcebo; Carboplatin; Etoposide；Radiotherapy · Oncology This is a combination regimen using carboplatin and etoposide chemotherapy plus radiotherapy to kill cancer cells through DNA damage and cell cycle disruption, with placebo as a control arm.
Pegylated rhG-CSF: 100µg/kg · Oncology; Hematology Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.
Placebo、5-Fluorouracil、Leucovorin · Oncology 5-Fluorouracil is a pyrimidine antimetabolite that inhibits thymidylate synthase and gets incorporated into RNA, disrupting nucleotide synthesis and cancer cell division, while leucovorin enhances its efficacy by stabilizing the drug-enzyme complex.
Placebo、Chemotherapeutic · Oncology This is a placebo control used in chemotherapy clinical trials to establish efficacy of an active chemotherapeutic agent.
placebo+chemotherapy · Oncology This drug works by enhancing the effects of chemotherapy.
Placebo, Trastuzumab, Docetaxel · Oncology This combination uses trastuzumab to block HER2 signaling in cancer cells while docetaxel disrupts microtubule dynamics to inhibit cell division, with placebo as a control arm.
Pregabalin Release Tablets · Neurology; Pain Management; Psychiatry Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.
Pyrotinib in combination with Capecitabine. · Oncology Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, and when combined with Capecitabine, it is used to treat HER2-positive breast cancer.
Pyrotinib, Trastuzumab, Docetaxel · Oncology Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, while Trastuzumab is a monoclonal antibody targeting the HER2 protein, and Docetaxel is a taxane inhibitor of microtubule assembly.
Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan · Oncology This is a combination regimen pairing ramucirumab (a VEGF receptor 2 inhibitor) with chemotherapy agents (paclitaxel, docetaxel, or irinotecan) to block tumor angiogenesis while simultaneously attacking cancer cells.
Retagliptin, Henagliflozein, metformin XR · Diabetes Retagliptin, Henagliflozein, and metformin XR work together to lower blood sugar levels by enhancing insulin secretion and suppressing glucagon release, and also by decreasing glucose reabsorption in the kidneys.
Rezvilutamide Tablets · Oncology Rezvilutamide is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.
Rivoceranib (Apatinib) · Oncology Rivoceranib (Apatinib) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2).
saline eye drops. · Ophthalmology Saline eye drops work by lubricating the eyes to help relieve dryness and irritation.
SHR-1209 · Oncology SHR-1209 is a humanized monoclonal antibody that blocks the interaction between PD-L1 and its receptors (PD-1 and B7-1) to enhance anti-tumor immune responses.
Phase 2 pipeline
Apatinib and Etoposide capsule · Oncology Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), while Etoposide is a topoisomerase inhibitor that works by interfering with the enzyme topoisomerase II, thereby inhibiting DNA replication and transcription.
FH-006 ; SHR-1316 ; BP102 · unknown FH-006 is a small molecule drug that targets the molecular target.
Fluzoparib Combined With Apatinib · Oncology Fluzoparib is a PARP inhibitor that blocks DNA repair, while apatinib is a VEGFR-2 inhibitor that inhibits angiogenesis, together potentially enhancing antitumor activity.
GEMOX · Oncology Gemcitabine and oxaliplatin combination chemotherapy